OBJECTIVE: The relationship between systemic sclerosis (SSc) and interleukin 23 (IL-23), a cytokine associated with the differentiation of T lymphocytes, is unknown. We investigated serum IL-23 levels and their clinical association in patients with SSc. METHODS: Serum IL-23 levels were examined by ELISA in 63 patients with SSc, 15 patients with systemic lupus erythematosus (SLE), and 31 healthy individuals. SSc patients comprised 25 with limited cutaneous SSc and 38 with diffuse cutaneous SSc. RESULTS: Serum IL-23 levels were significantly elevated in SSc patients compared to patients with SLE (p < 0.05) and controls (p < 0.005). Elevated serum IL-23 levels were associated with the disease duration (p < 0.05) and the prevalence of pulmonary fibrosis (p < 0.05), although they were not associated with other clinical features, including the extent of skin sclerosis or the severity of pulmonary fibrosis. CONCLUSION: The results suggest that IL-23 is associated with induction of SSc and that blockade of IL-23 can be a potential therapeutic strategy in early SSc.
OBJECTIVE: The relationship between systemic sclerosis (SSc) and interleukin 23 (IL-23), a cytokine associated with the differentiation of T lymphocytes, is unknown. We investigated serum IL-23 levels and their clinical association in patients with SSc. METHODS: Serum IL-23 levels were examined by ELISA in 63 patients with SSc, 15 patients with systemic lupus erythematosus (SLE), and 31 healthy individuals. SSc patients comprised 25 with limited cutaneous SSc and 38 with diffuse cutaneous SSc. RESULTS: Serum IL-23 levels were significantly elevated in SSc patients compared to patients with SLE (p < 0.05) and controls (p < 0.005). Elevated serum IL-23 levels were associated with the disease duration (p < 0.05) and the prevalence of pulmonary fibrosis (p < 0.05), although they were not associated with other clinical features, including the extent of skin sclerosis or the severity of pulmonary fibrosis. CONCLUSION: The results suggest that IL-23 is associated with induction of SSc and that blockade of IL-23 can be a potential therapeutic strategy in early SSc.
Authors: Sandeep K Agarwal; Pravitt Gourh; Sanjay Shete; Gene Paz; Dipal Divecha; John D Reveille; Shervin Assassi; Filemon K Tan; Maureen D Mayes; Frank C Arnett Journal: J Rheumatol Date: 2009-11-16 Impact factor: 4.666
Authors: Paméla Gasse; Nicolas Riteau; Rachel Vacher; Marie-Laure Michel; Alain Fautrel; Franco di Padova; Lizette Fick; Sabine Charron; Vincent Lagente; Gérard Eberl; Marc Le Bert; Valérie F J Quesniaux; François Huaux; Maria Leite-de-Moraes; Bernhard Ryffel; Isabelle Couillin Journal: PLoS One Date: 2011-08-16 Impact factor: 3.240
Authors: Pravitt Gourh; Frank C Arnett; Shervin Assassi; Filemon K Tan; Mei Huang; Laura Diekman; Maureen D Mayes; John D Reveille; Sandeep K Agarwal Journal: Arthritis Res Ther Date: 2009-10-02 Impact factor: 5.156
Authors: Aleksandra Dańczak-Pazdrowska; Michał Kowalczyk; Beata Szramka-Pawlak; Justyna Gornowicz-Porowska; Aleksandra Szewczyk; Wojciech Silny; Anna Olewicz-Gawlik; Marta Molińska-Glura; Ryszard Zaba; Paweł Hrycaj Journal: Arch Med Sci Date: 2012-12-19 Impact factor: 3.318